
Web Release Date: April 19,
Chemical Insights in the Concept of Hybrid Drugs: The Antitumor Effect of Nitric Oxide-Donating Aspirin Involves A Quinone Methide but Not Nitric Oxide nor Aspirin








and

Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, and Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
Received November 28, 2006
Abstract:
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to current beliefs, neither ASA nor NO contributes to this antitumor effect. Rather, an unsubstituted QM was identified as the sole cytotoxic agent. QM forms from 1 after carboxylic ester hydrolysis and, in accordance with the HSAB theory, selectively reacts with cellular GSH, which in turn triggers cell death. Remarkably, a derivative lacking ASA and the -ONO2 group is 10 times more effective than 1. Thus, our data provide a conclusive molecular mechanism for the antitumor activity of 1. Equally importantly, we show for the first time that a "presumed invisible" linker in a hybrid drug is not so invisible after all and is in fact solely responsible for the biological effect.
Medicinal research is constantly seeking to improve the
efficiency of drugs. One approach involves the use of so-called
hybrid drugs, which comprises the incorporation of two drug
pharmacophores in one single molecule with the intention to
exert dual drug action.1 For example, one of the hybrid parts
may be incorporated to counterbalance the known side effects
associated with the other hybrid part, or to amplify its effect
through action on another biotarget. Some hybrid drugs are
designed to interact with multiple targets as one single molecule,
and others require prior disintegration to afford the active hybrid
components. An archetypical example of the latter class is NO-ASAa, which consists of ASA and a nitrate group (-ONO2) as
a NO donor connected by a spacer (Scheme 1). Its development
was based on the assumption that carboxylic ester hydrolysis
would afford ASA and an NO-donating moiety. The resulting
advantage is that the known gastrointestinal side effects of ASA
would be reduced by this concomitant release of NO (NO-hybrid
theory).2 A possible application for such hybrids is in the area
of chemoprevention, because ASA is a known moderately active
chemopreventive agent.3 Two NO-ASA isomers, 1 (para-isomer) and 3 (ortho-isomer), were indeed found to be highly
effective in inhibiting growth of colon cancer both in vitro and
in vivo.4,5
However, we reasoned that the induction of apoptosis cannot be explained by a hybrid action because of conflicting mechanistic results in the literature. For example, upon treatment with 1, cGMP levels do not increase while this is a typical effect of NO release.15 Moreover, nitrate esters of seven other NSAIDs induce considerably less apoptosis compared to 1.16 These conflicting results inspired us to probe the mechanism of action for 1 from a detailed molecular point of view by investigating a set of small-molecule analogues obtained through stepwise omission of the hybrid components. Toward this end, we used organic-chemical, computational, and biochemical approaches as well as 1H and 15N NMR spectroscopy. In this report, we disclose our surprising finding that the designer hybrid drug 1, paradoxally, is not a hybrid drug after all.
Synthesis and Activity of Model Compounds. As previously
reported, meta-isomer 2 is less active than its positional isomers
(1 and 3) in inducing apoptosis in colon cancer cells.5 This
important finding suggests a crucial role for aromatic resonance
interaction. Therefore, we selected model compounds having
both a para- or meta-substituted aromatic core. The general
synthesis of these compounds, and of additional compounds
discussed later in this paper, is outlined in Scheme 1. The
appropriate hydroxybenzaldehyde was acylated with RCOOCl,
and the resulting aldehyde was smoothly reduced with NaBH4
in THF in good yields. The benzylic alcohol thus obtained was
chlorinated with the aid of SOCl2. A final substitution reaction
with AgNO3 in MeCN yielded the desired nitrate compounds.
Initially, the selection of model compounds of 1 involved the
replacement of the ASA-ester by an acetyl ester (7a) and of
the nitrate moiety by an alcohol group (5c). Their activities were
investigated by measuring the extent of cell death they induce
in HT29 colon cancer cells after a 24 h incubation. As can be
seen from Figure 1A, reference compounds ASA, meta-isomer
2, and conventional NO-donor SNAP were less active than 1
in inducing cell death. In sharp contrast, acetyl ester 7a is
considerably more active than 1, indicating that the ASA ester
is not required and that a less bulky ester increases activity
(Figure 1B). Replacement of the nitrate group by an alcohol
(5c) was detrimental for activity, a finding disclosed previously
by others.5 However, compared to an alcohol, the more electron-withdrawing nitrate group imposes a different chemical reactivity onto the neighboring carbon atom. This led us to recognize
that the core skeletons of 1 and 7a in fact satisfy the
requirements for precursors to the class of para-QMs. The
design of a few such precursors has been described,17,18
with NO3- as the leaving group (Scheme 2A).
Rate-determining hydrolysis of the carboxylic ester group, likely catalyzed by esterases, gives phenolate 8, which at pH 7.4 can either reversibly bind a proton or it can rapidly and irreversibly undergo a 1,6-elimination,18 with formation of QM 10 and the biologically inert nitrate ion. QM 10 represents the simplest para-QM conceivable. It has been studied before in P450 oxidations of p-cresol, where it is detected as a significant metabolite.22 From those studies, it is known to react mostly with H2O and cytoplasmic GSH yielding benzylalcohol 11a and GSH-adduct 12, respectively, the latter being the predominant product. This trapping of GSH by 10 to 12 is reported to lead to pronounced toxic effects.22
Mechanistic Studies on Quinone Methide Formation. QM
formation from para-substituted benzylnitrates such as 1 and
7a is a hitherto unknown transformation. We studied key steps
in this process in theoretical and practical settings. To prove
the role of the leaving group for the -ONO2 moiety, similar
molecules with a chloride atom as an alternative good leaving
group (i.e., 6a-c and 13, see Schemes 1 and 2B) were studied
as well. Linear transit calculations were conducted on the proton
abstraction from phenols 9 and 13 by HO- ion using DFT23 at
the BLYP level. These calculations reveal that, upon deprotonation of phenols 9 and 13, the resulting phenolates 8 and 14
at 37
C undergo a rapid and energetically favorable [1,6]-elimination of the leaving group, thereby generating QM 10
(see Supporting Information for graph and details). In contrast,
derivatives of 9 and 13 in which deprotonation of the phenol
group is hindered by flanking tert-butyl groups are known to
be stable and can be isolated.24,25
C, that is, 6b and 7b were stable, whereas 6a
and 7a completely reacted to benzylic alcohol 11a within hours
(data not shown). These findings fully match previous reports
on the differences in reactivity of analogous acetyl and pivaloyl
esters with a phosphate leaving group.26
To investigate the reactivity profiles of the electrophilic
species formed after carboxylic ester hydrolysis, a set of test
compounds was incubated in D2O (pD 7.4) at 37
C in the
presence of NAC (4 equiv) as a GSH model.27 In these studies,
dissolution and carboxylic ester hydrolysis are the slow steps,
whereas any reactive electrophile formed will be trapped by
either NAC or water, thereby providing a useful molecular in
situ snapshot. Upon consumption of starting material (footnote
b, Table 1), the mixtures were analyzed by 15N NMR or by 1H
NMR, focusing on the shifts for the benzylic groups (Figure
2B,C). The NAC (19a-c)28 and water (11a-c) conjugation
products, the ratio of which is defined as the S/O ratio, accounted
for >85% of products, except in the case of 15, where the mass
balance was 73%.29 Noteworthy, no significant amounts of
theoretically possible regioisomeric NAC addition products, such
as resulting from direct addition to the ring of 10, were observed
by NMR nor LC-MS. Interestingly, the obtained S/O ratios
(Table 1) can be clearly interpreted using the HSAB theory.30
Compounds with a para-ester (1, 6c, 7a, 6a) selectivity yielded
NAC-adducts (S/O > 10, clearly visible in Figure 2B), whereas
meta-esters (2, 7d) preferentially yielded water-adducts (S/O
< 1, clearly visible in Figure 2C). Interestingly, reaction of para-MeO-BnCl (15) via a SN1 substitution through hard cation 16
gave an S/O ratio <0.2. This strongly suggests that direct SN1
reaction of NAC or water with 9 through hard cation 17, which
is very similar to 16, is not involved (Scheme 2A). In fact, these
data further strengthen the case for soft QM 10 as reactive
intermediate because it prefers thiols. The meta compounds,
structurally not able to form QMs, preferentially react with water
through SN2 on phenol 18 while expelling the hard nitrate ion.
Incubation of 6a with GSH gave a slightly higher bias toward
the S-adducts compared to NAC,27 but analysis was complex
due to extensive overlap of 1H NMR signals. Last, 15N-labeled
7a (i.e., 20) gave a single 15N peak at 376.7 ppm (see Supporting
Information), which corresponds to the 15NO3- ion. This
confirms that nitrate only acts as a leaving group and that NO
is not generated from thiols and 7a at pH 7.4 (oxidation of
liberated 15NO in buffer leads to 15NO2- ions,31 which would
give a signal at 609 ppm32).
Studies on the Apoptotic Activity of Quinone Methide.
The discussed chemical studies clearly suggest that removal of
one of the hybrid components from 1 (i.e., giving 6c and 7a)
does not qualitatively change its chemical behavior toward
cellular nucleophiles GSH and H2O as all proceed through QM
10. Interestingly, the same holds true for compound 6a in which
both hybrid components have been removed. We therefore
speculated that all compounds with high S/O ratios exert
apoptotic effects simply through the action of 10. Indeed, while
our work was in progress, others reported that apoptosis
induction by NO-ASA involves GSH depletion,13 thereby further
substantiating the key role we hypothesized for QM 10. To
deliver definite proof for this hypothesis, the three key model
compounds (6c, 7a, and 6a) were tested together with 1 and
meta-NO-ASA (2) on HT29 cells in selected pharmacological
studies. Figure 3A,B show the measured EC50 values for all
five compounds. Compound 6c is about 2-fold more active than
1 in inducing cell death. More intriguingly, for 6a and 7a, this
increase in apoptotic effect is a remarkable 10-fold. We attribute
the latter to the higher sensitivity of small acetyl esters toward
hydrolysis as compared to the bulkier ASA esters. Just as is
the case for 1, GSH depletion plays a key role in the case of
cell death by 6a, 6c, and 7a because intracellular GSH levels
decreased significantly upon treatment with these compounds,
whereas 2 did not induce this depletion (Figure 5A). Again,
the small acetyl esters 6a and 7a are the most active. Another
hallmark consequence of GSH depletion by NO-ASA is
activation of caspase-3.13 Indeed, 1, 6c, 7a, and 6a all induced
cleavage of the typical caspase-3 substrate PARP, whereas, in
contrast, 2 did not lead to significant PARP cleavage even at
300
M (Figure 3C). The apoptotic pathway was investigated
in further detail for 1 and 6a. Both compounds induce DNA
fragmentation in HT29 cells as measured with the Nicoletti assay
(Figure 4). Furthermore, the apoptotic pathway induced by 1
and 6a follows a typical mitochondrial-dependent mechanism.
That is, Jurkat cells overexpressing Bcl-2 resist cell death
induced by either compound and cell death induction was
insensitive to the deletion of the adaptor molecule FADD (see
Supporting Information). All these experiments clearly indicate
that deletion of both the -ONO2 group and ASA from 1 does
not change the mechanism by which cell death is induced.
Moreover, they confirm the notion that apoptotic features are
induced by 6a at lower concentrations than by 1. It should be
noted that GSH depletion can generally trigger both apoptosis
and necrosis, depending on the circumstances.33 We believe that
at higher concentrations of our drugs, necrosis might be induced
as indicated by low staining by an apoptosis-sensitive dye (data
not shown), visual inspection of cell death, and decreasing
intensity in Western blots (Figure 3C,D).
In addition to the discussed cytotoxic effects, compound 1
was also shown to induce cytostatic effects as it interferes with
the interaction of
-catenin with Tcf in SW480 colon carcinoma
cells.13 We tested the serum-induced expression of cyclin D1,
which is dependent on
-catenin/Tcf,13 and found that inhibition
of cyclin D1 induction is observed with 1, 6a, 6c, and 7a, while
2 is ineffective (Figure 3D).
The key GSH depletion through covalent adduct 12 was
substantiated in more molecular detail for 1 and for 6a (devoid
of both ASA and -ONO2 group). Pretreatment of HT29 cells
with GSH-synthesis inhibitor BSO34 increased the sensitivity
of the cells toward cell death by 1 and 6a, whereas replenishment with EtGSH34 partially prevented this effect (Figure 5B).
This reconfirms that GSH depletion is a major active contributor
to the sequence leading to cell death. Previous metabolic studies
on 1 only provided UV and MS evidence for key adduct 12,
but the lack of authentic 12 prevented unequivocal confirmation
of the proposed molecular structure.35 We synthesized 12 from
GSH and 6a, isolated it by LC-MS (55% extrapolated yield),
and confirmed its structure by 2D-NMR and MS (Figure 5C
and Supporting Information). The use of this standard enabled
unequivocal assignment of 12 as the major GSH-QM adduct
formed upon incubation of 1 or 6a (both 100
M) with HT29
cells (Figure 5D). The virtual absence of other peaks in the LC
trace (detection at m/z = 414) strongly suggests that no other
regioisomeric GSH adducts have been formed in the cell
incubations, which is in accordance with the NAC incubation
studies (vide supra). Lowering the drug concentration to 30
M
led to 4-5 times less 12 (see Supporting Information). All these
observations underscore that the similarity of mode of action
between 1 and 6a starts at the basal molecular level by their
similar ability to provide a selective GSH-consuming metabolite
(high S/O ratio), and this similarity is then amplified in downstream processes. Analogously, the lack of 2 to induce comparable cell death is a direct result of the lower chemical
tendency of its metabolite (18) to bind GSH (low S/O ratio).
Thus, hydrolysis of the phenolic ester triggers the chemical
cascade, and the extent of GSH conjugation and the resulting
apoptotic, necrotic, and transcriptional effects simply reflect the
intrinsic physiochemical properties of the electrophiles formed
immediately after carboxylic ester hydrolysis. That is, the
cytotoxic species is formed from the chemical linker and not
from any of the hybrid components. As such, this represents a
major departure from the hybrid theory on which the design of
1 was based.36 Last, we note that 1 has been specifically used
as NO-donor in recent research.37,38
The initial sequence of molecular events underlying the antitumor activity of an archetypical hybrid drug, i.e. preclinical candidate 1, and the lack thereof for the meta-isomer 2, have been elucidated and were shown to be almost completely dictated by the physical-organic HSAB principle. Remarkably, no role in the activity for NO or ASA was identified. Rather, the mechanism allows for the antitumor effect to be generalized to any phenyl ester possessing a para-methylene with a leaving group L (Figure 6). Thus, rate-determining carboxylic ester hydrolysis is followed by a rapid chain of events that ultimately leads to formation of an unsubstituted QM. This QM reacts with GSH, in response to which the cell initiates a variety of signaling pathways leading to cytotoxic and cytostatic effects. In their own right, any of such precursors to QM could be interesting for clinical purposes provided the carboxylic ester group is appropriately tuned toward localized cleavage. Equally important, the identification of the NO-donating group and ASA as passive bystanders and a quinone methide as the unexpected active agent should send out a clear warning signal to the promising field of hybrid drug research: caution should be exercised when selecting the (ideally) noninterfering spacer.
| Figure 6 Overall mechanism of action for 1 and 6a as well as for any other precursor to QM 10. L = leaving group. |
Chemicals. Unless noted otherwise, all chemicals or reagents
were purchased from Sigma-Aldrich. Growth medium consisted
of IMDM (Cambrex) with 8% FCS (Cambrex, heated prior to use
to deactivate esterases), glutamine (Cambrex), and Pen-Strep
(Gibco). PI was purchased from Molecular Probes. Aprotinin and
Lumilight were obtained from Roche, and leupeptin was from
Boehringer-Mannheim. Primary antibodies against PARP were
purchased from Cell Signaling Technology, antibodies for actin
were from Santa Cruz Biotechnology, antibodies for cyclin D1 were
from BD Transduction Laboratories, and secondary HRP-linked
swine-
-rabbit or goat-
-mouse antibodies were obtained from
DAKO.
Computational Methods. All calculations were performed using
ADF 2004.01.23,39 A double-
core, triple-
valence, and doubly
polarized basis set (TZ2P) was used. The Becke40 exchange
functional was used in combination with the LYP correlation
functional41 and ZORA relativistic corrections.42 Calculations were
performed in the gas phase or with inclusion of implicit solvent
medium. The latter was carried out with the conductor-like
screening model (COSMO) of salvation.43,44
Cell Line. HT-29 or SW480 colon adenocarcinoma cells or Jurkat cells were used. Cells were counted using a cell counter from Bürker. Viability was determined by the trypan blue dye exclusion method.
Cell Death Assay by PI Exclusion. pEC50 Curves: Cells were
seeded (25 000/well) and allowed to attach for 24 h. The supernatant
was replaced by 1.0 mL medium pretreated with a DMSO solution
of the compound (0-1000
M, 5.0
L). The final DMSO
concentration for all experiments was 0.5%, except for the 600
M
experiment, where it was 1.0%. After 24 h of stimulation at 37
C,
the supernatant was collected and the cells were washed with PBS
(400
L) and detached with 400
L TE (trypsin EDTA). The
supernatant, PBS, and TE were centrifuged (1200 rpm for 5 min
at 4
C), and the supernatant was removed. Subsequently, the cells
were treated with 50
L BSA with PI (1:1000). After incubation
for 10 min, the cells were analyzed for PI positivity by flow
cytometry using the software "Cellquest". For each condition,
10 000 events were analyzed. Cells negative to PI were considered
living and used for calculation of the EC50, which was done with
Prism software. BSO/EtGSH Experiments: Cells were seeded
(25 000/well) and allowed to attach for 24 h. The supernatant was
replaced by 1.0 mL medium with or without 200
M BSO. After
4 h at 37
C, the medium was removed and the cells were washed
with warm PBS (1.0 mL). Subsequently, 0.5 mL of medium with
or without EtGSH (10 mM) was added. After 3 h at 37
C, the
medium was removed and the cells were washed with warm PBS
(1.0 mL). Then they were stimulated with the compounds and
assayed as described above. Jurkat-Bcl-2 Experiments: Jurkat-neo or Bcl-2 transfectants were treated with the indicated concentrations of compound 1 and 6a at a density of 1 million/mL for 20
h, and cell death was directly analyzed by PI as described above.
Fadd Experiments: Jurkat clone JA3 or the corresponding FADD
knockout clone (FADD-/-) were treated with anti-APO-1 (anti-Fas) to control for the efficacy of FADD deletion, as Fas-induced
death completely depends on the presence of FADD, or with
compound 1 and 6a. After 20 h, cell death was analyzed using PI
exclusion as described above.
DNA Fragmentation/Nicoletti Assay. HT29 cells were seeded
at a density of 25 000/well and allowed to attach for 24 h. After
this, the cells were treated with the indicated amount of compound
1 or 6a. After 48 h, the cells were trypsinized and resuspended in
Nicoletti buffer (0.1%Tx-100, 0.1% NaCitrate and 50
g/mL PI).
After overnight incubation at 4
C, the DNA content of the
remaining nuclei was determined using FACS and Cellquest
software.
Cellular GSH Levels. GSH levels were determined using
Ellman's reagent (5,5'-dithio-bis(2-nitrobenzoic acid, DTNB). In
short, HT-29 cells were seeded in a 6-well plate (106 cells/well) in
2 mL of medium. After treatment with the different compounds
for 1 h at 37
C, cells were harvested, washed once with PBS, and
then lysed on ice in 40
L of Triton X-100 lysis buffer without
proteinase inhibitors. Lysates were cleared by centrifugation and
intracellular GSH was measured in triplicate (10
L of sample
mixed with 50
L of Ellman's reagent (0.5 mM DTNB) in HEPES
buffer (0.5 M HEPES pH 7.5, 0.1 M NaCl, 0.05% Triton-X-100).
The amount of GSH was quantified by measuring the absorbance
at 405 nm in a microtiterplate reader (BioRad) and by using a
standard curve of GSH. Percentages of GSH content from treated
cells are compared to basal GSH content measured in untreated
cells.
LC-MS Analysis of Cell Lysates. Equipment: A Shimadzu
SCL-10A/Finnigan LC-QPeca with a Phenomenex Luna 5
C18
(150 × 4.60 mm, 5
) column was used, with the following gradient
(A = 98.8% H2O, 1% MeCN, and 0.2% HCOOH; B = 98.8%
MeCN, 1% H2O, and 0.2% HCOOH): 0
5 min, 0% B; 5
30
min, 0
100% B; 30
35 min, 100
0% B; 35
40 min, 0%
B. The flow rate was 0.4 mL/min, and detection was conducted at
m/z 414 (ionization: ESI, full MS, positive mode) or UV absorption
at 254 nm. Procedure: Cells were seeded (1.2 × 106/well) in 3
mL of medium and allowed to attach for 24 h. The supernatant
was replaced by 1.8 mL of medium containing the compound in
DMSO (final DMSO content 0.5%). For the blank, only DMSO
was used. After 24 h of stimulation at 37
C, the supernatant was
collected and the well was washed with PBS (0.35 mL). To the
mixed supernatant and washing, 250
L of TE was added. After
detachment of the cells, 750
L of medium and 350
L of 10%
HClO4 solution was added. The contents were mixed thoroughly
by vortexing for 3 min, and high-molecular material was removed
by sequential centrifugation (4000 rpm/20 min, then 14 000/15 min).
The supernatant was immediately stored at -78
C until analysis.
Upon analysis, 20
L was injected and the peak for 12 (at 19.8
min) was analyzed. Coinjection with authentic 12 was used to
confirm peak identity, and amounts were calculated by using the
mass areas for authentic 12.
We thank Michael Bots, Saskia Hulscher, Keren Borensztajn, Martin R. Sprick and Matthias Bickelhaupt for valuable advice, Frans de Kanter for conducting NMR analysis for the NAC incubations and Michaela Damsten for assistance with LC-MS analysis.
Purity table, graph and additional details on computational chemistry, differences in reactivity between acetyl ester 7a and pivaloyl ester 7b, HPLC retention times and exact yields of the NAC incubation studies, detailed investigations on apoptotic pathway induced by 1 and 6a, yields of adduct 12 in HT29 cell lysates, incubation of 20 with NAC, detailed synthetic procedures, protocols for NAC-incubation assays and Western blots, and full analytical data for all synthesized compounds. This material is available free of charge via the Internet at http://pubs.acs.org.
* To whom correspondence should be addressed. Phone: +31(0)20-5987603. Fax: +31(0)20-5987610. E-mail: wijtmans@few.vu.nl.
University of Amsterdam.
Vrije Universiteit Amsterdam.
These authors contributed equally.
a. Abbreviations: ASA, aspirin; BSO, DL-buthionine(S,R)-sulfoximine; cGMP, cyclic guanosine monophosphate; DFT, density functional theory; EtGSH, GSH ethyl ester; FACS, fluorescence-activated cell sorter; FADD, Fas associated protein with a death domain; GSH, glutathione; HSAB, hard-soft acid-base; iNOS, inducible nitric oxide synthase; MAPK, mitogen-activated protein kinase; NAC, N-acetyl-L-cysteine; NO, nitric oxide; NO-ASA, nitric oxide-donating aspirin; NSAID, nonsteroidal anti-inflammatory drug; PARP, poly(ADP-ribose) polymerase; PI, propidium iodide; QM, quinone methide; SNAP, S-nitroso-N-acetylpenicillamine; Tcf, T-cell factor; ZORA, zeroth-order regular approximation.
1. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed
multiple ligands. Drug Discovery Today 2004, 9, 641-651.
2. Bolla, M.; Almirante, N.; Benedini, F. Therapeutic potential of nitrate
esters of commonly used drugs. Curr. Top. Med. Chem. 2005, 88,
707-720.
3. Baron, J. A.; Cole, B. F.; Sandler, R. S.; Haile, R. W.; Ahnen, D.;
Bresalier, R.; McKeown-Eyssen, G.; Summers, R. W.; Rothstein,
R.; Burke, C. A.; Snover, D. C.; Church, T. R.; Allen, J. I.; Beach,
M.; Beck, G. J.; Bond, J. H.; Byers, T.; Greenberg, E. R.; Mandel,
J. S.; Marcon, N.; Mott, L. A.; Pearson, L.; Saibil, F.; van Stolk, R.
U. A randomized trial of aspirin to prevent colorectal adenomas. N.
Engl. J. Med. 2003, 348, 891-899.
4. Williams, J. L.; Kashfi, K.; Ouyang, N.; del Soldato, P.; Kopelovich,
L.; Rigas, B. NO-donating aspirin inhibits intestinal carcinogenesis
in Min (APCMin/+) mice. Biochem. Biophys. Res. Comm. 2004, 313,
784-788.
5. Kashfi, K.; Borgo, S.; Williams, J. L.; Chen, J.; Gao, J.; Glekas, A.;
Benedini, F.; del Soldato, P.; Rigas, B. Positional isomerism markedly
affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharm. Exp. Ther. 2005,
312, 978-988.
6. Kashfi, K.; Ryann, Y.; Qiao, L. L.; Williams, J. L.; Chen, J.; Del
Soldato, P.; Traganos, F.; Rigas, B. Nitric oxide-donating nonsteroidal
anti-inflammatory drugs inhibit the growth of various cultured human
cancer cells: Evidence of a tissue type-independent effect. J. Pharm.
Exp. Ther. 2002, 303, 1273-1282.
7. Huguenin, S.; Vacherot, F.; Fleury-Feith, F.; Riffaud, J-P.; Chopin,
D. K.; Bolla, M.; Jaurand, M-C. Evaluation of the antitumoral
potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines.
Cancer Lett. 2005, 218, 163-170.
8. Tesei, A.; Ulivi, P.; Fabbri, F.; Rosetti, M.; Leonetti, C.; Scarsella,
M.; Zupi, G.; Amadori, D.; Bolla, M.; Zoli, W. In vitro and in vivo
evaluation of NCX 4040 cytotoxic activity in human colon cancer
cell lines. J. Transl. Med. 2005, 3, 7-18.
9. Hundley, T. R.; Rigas, B. Nitric oxide-donating aspirin inhibits colon
cancer cell growth via mitogen-activated protein kinase activation.
J. Pharm. Exp. Ther. 2006, 316, 25-34.
10. Rosetti, M.; Tesei, A.; Ulivi, P.; Fabbri, F.; Vannini, I.; Brigliadori,
G.; Amadori, D.; Bolla, M.; Zoli, W. Molecular characterization of
cytotoxic and resistance mechanisms induced by NCX 4040, a novel
NO-NSAID, in pancreatic cancer cell lines. Apoptosis 2006, 11,
1321-1330.
11. Leonetti, C.; Scarsella, M.; Zupi, G.; Zoli, W.; Amadori, D.; Medri,
L.; Fabbri, F.; Rosetti, M.; Ulivi, P.; Cecconetto, L.; Bolla, M.; Tesei,
A. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory
drug and cytotoxic drugs in human colon cancer cell lines in vitro
and xenografts. Mol. Cancer Ther. 2006, 5, 919-926.
12. Spiegel, A.; Hundley, T. R.; Chen, J.; Gao, J.; Ouyang, N.; Liu, X.;
Go, M. F.; Tsioulias, G. J.; Kashfi, K.; Rigas, B. NO-donating aspirin
inhibits both the expression and catalytic activity of inducible nitric
oxide synthase in HT-29 human colon cancer cells. Biochem. Pharm.
2005, 70, 993-1000.
13. Gao, J.; Liu, X.; Rigas, B. Nitric oxide-donating aspirin induces
apoptosis in human colon cancer cells through induction of oxidative
stress. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17207-17212.
14. Tanaka, T.; Kurose, A.; Halicka, H. D.; Huang, X.; Traganos, F.;
Darzynkiewicz, Z. Nitrogen oxide-releasing aspirin induces histone
H2AX phosphorylation, ATM activation and apoptosis preferentially
in S-Phase cells. Cell Cycle 2006, 5, 1669-1674.
15. Williams, J. L.; Nath, N.; Chen, J.; Hundley, J. R.; Gao, J.;
Kopelovich, L.; Kashfi, K.; Rigas, B. Growth inhibition of human
colon cancer cells by nitric oxide (NO)-donating aspirin is associated
with cyclooxygenase-2 induction and
-catenin/T-Cell factor signaling, nuclear factor-
B, and NO synthase 2 inhibition: Implications
for chemoprevention. Cancer Res. 2003, 63, 7613-7618.
16. Yeh, R. K.; Chen, J.; Williams, J. L.; Baluch, M.; Hundley, T. R.;
Rosenbaum, R. E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato,
P.; Kashfi, K.; Rigas, B. NO-donating nonsteroidal antiinflammatory
drugs (NSAIDs) inhibit colon cancer cell growth more potently than
traditional NSAIDs: a general pharmacological property? Biochem.
Pharm. 2004, 67, 2197-2205.
17. Dyer, R. G.; Turnbull, K. D. Hydrolytic stabilization of protected
p-hydroxybenzyl halides designed as latent quinone methide precursors. J. Org. Chem. 1999, 64, 7988-7995.
18. Wakselman, M. 1,6 and 1,4 eliminations from hydroxyl- and amino-substituted benzyl systems: Chemical and biochemical applications.
Nouv. J. Chem. 1983, 7, 439-447.
19. Thompson, D. C.; Thompson, J. A.; Sugumaran, M.; Moldéus, P.
Biological and toxicological consequences of quinone methide
formation. Chem.-Biol. Interact. 1992, 86, 129-162.
20. Bolton, J. L.; Valerio, L. G., Jr.; Thompson, J. A. The enzymatic
formation and chemical reactivity of quinone methides correlate with
alkylphenol-induced toxicity in rat hepatocytes. Chem. Res. Toxicol.
1992, 5, 816-822.
21. Kupchan, S. M.; Karim, A.; Marcks, C. Taxodione and Taxodone,
two novel diterpenoid quinone methide tumor inhibitors from
Tuxodium distichum. J. Am. Chem. Soc. 1968, 90, 5923-5924.
22. Thompson, D. C.; Perera, K.; London, R. Quinone methide formation
from para isomers of methylphenol (cresol), ethylphenol and
isopropylphenol: Relationship to toxicity. Chem. Res. Toxicol. 1995,
8, 55-60.
23. Te Velde, G.; Bickelhaupt, F. M.; Baerends, E. J.; Fonseca Guerra,
C.; van Gisbergen, S. J. A.; Snijders, J. G.; Ziegler, T. Chemistry
with ADF. J. Comput. Chem. 2001, 22, 931-967.
24. Roni
n, A.; Parker, V. D. Anodic oxidation of phenolic compounds.
Part II. Products and mechanism of the anodic oxidation of hindered
phenols. J. Chem. Soc. C 1971, 3214-3218.
25. Satgé de Caro, P.; Mouloungi, Z.; Gaset, A. Synthesis of derivatives
of alkylamino alkyloxy propanol structures by N-alkylation, acylation,
and nitration. Application as fuel additives. J. Am. Oil Chem. Soc.
1997, 74, 241-247.
26. Mitchell, A. G.; Thornson, W.; Nicholls, D.; Irwin, W. J.; Freeman,
S. Bioreversible protection for the phospho group: Bioactivation of
the di(4-acyloxybenzyl) and mono(4-acyloxybenzyl) phosphoesters
of methyl phosphonate and phosphonoacetate. J. Chem. Soc., Perkin
Trans. 1 1992, 2345-2353.
27. GSH incubations were less useful as the diagnostic ArCH2S group
of 12 is buried under other GSH peaks and cannot be easily
quantified. NAC and GSH behave similarly in conjugations of
polysubstituted quinone methides, although GSH can be slightly more
reactive. See, for example: Awad, H. M.; Boersma, M. G.; Boeren,
S.; van Bladeren, P. J.; Vervoort, J.; Rietjens, I. M. C. M. Quenching
of quercetin quinone/quinone methides by different thiolate scavengers: stability and reversibility of conjugate formation. Chem. Res.
Toxicol. 2003, 16, 822-831.
28. Reference adduct 19a was obtained by reacting NAC with 4-hydroxybenzylalcohol in refluxing acetic acid.
29. In the case of incubation of 15, the most abundant products were the water adduct 11c and, surprisingly, N-N'-di-p-OMe-benzylated cystine.
30. Pearson, R. G. Hard and soft acids and bases. J. Am. Chem. Soc.
1963, 85, 3534-3539.
31. Ignarro, L. J.; Fukuto, J. M.; Griscavage, J. M.; Rogers, N. E.; Byrns,
R. E. Oxidation of nitric oxide in aqueous solution to nitrite but not
nitrate: Comparison with enzymatically formed nitric oxide from
l-arginine. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8103-8107.
32. Butler, A. R.; Rutherford, T. J.; Shorta, D. M.; Ridd, J. H. Tyrosine
nitration and peroxonitrite (peroxynitrite) isomerisation: 15N CIDNP
NMR Studies. Chem. Commun. 1997, 669-670.
33. Higuchi, Y. Glutathione depletion-induced chromosomal DNA
fragmentation associated with apoptosis and necrosis. J. Cell. Mol.
Med. 2004, 8, 455-464.
34. Meurette, O.; Lefeuvre-Orfila, L.; Rebillard, A.; Lagadic-Gossmann,
D.; Dimanche-Boitrel, M-T. Role of intracellular glutathione in cell
sensitivity to the apoptosis induced by tumor necrosis factor
-related
apoptosis-inducing ligand/anticancer drug combinations. Clin. Cancer
Res. 2005, 11, 3075-3083.
35. Gao, J.; Kashfi, K.; Rigas, B. In vitro metabolism of nitric oxide-donating aspirin: The effect of positional isomerism. J. Pharm. Exp.
Ther. 2005, 312, 989-997.
36. It should be mentioned that, by the time we were wrapping up this project after successfully proving the quinone methide theory, a WO patent (WO2005065361) became accessible in which one inventor of NO-ASA claims the use of NO-ASA as quinone methide precursor. However, this quinone methide has never been implicated in any of the many mechanistic studies on the effect of NO-ASA performed by the inventors.
37. Mancina, R.; Filippi, S.; Marini, M.; Morelli, A.; Vignozzi, L.;
Salonia, A.; Montorsi, F.; Mondaini, N.; Vannelli, G. B.; Donati, S.;
Lotti, F.; Forti, G.; Maggi, M. Expression and functional activity of
phosphodiesterase type 5 in human and rabbit vas deferens. Mol.
Hum. Reprod. 2005, 11, 107-115.
38. Morelli, A.; Filippi, S.; Mancina, R.; Luconi, M.; Vignozzi, L.;
Marini, M.; Orlando, C.; Vannelli, B.; Aversa, A.; Natali, A.; Forti,
G.; Giorgi, M.; Jannini, E. A.; Ledda, F.; Maggi, M. Androgens
regulate phosphodiesterase type 5 expression and functional activity
in corpora cavernosa. Endocrinology 2004, 145, 2253-2263.
39. ADF2004.01, SCM; Theoretical Chemistry; Vrije Universiteit: Amsterdam, The Netherlands (http://www.scm.com).
40. Becke, A. D. Density-functional exchange-energy approximation with
correct asymptotic-behavior. Phys. Rev. A: At., Mol., Opt. Phys.
1988, 38, 3098-3100.
41. Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti
correlation-energy formula into a functional of the electron density.
Phys. Rev. B: Condens. Matter 1988, 37, 785-789.
42. van Lenthe, E.; Ehlers, A. E.; Baerends, E. Geometry optimizations
in the zero order regular approximation for relativistic effects. J.
Chem. Phys. 1999, 110, 8943-8953.
43. Klamt, A.; Schüürmann, G. COSMO: A new approach to dielectric
screening in solvents with explicit expressions for the screening
energy and its gradient. J. Chem. Soc., Perkin Trans. 2 1993, 799-805.
44. Klamt, A. Conductor-like Screening Model for real solvents: A new
approach to the quantitative calculation of solvation phenomena. J.
Phys. Chem. 1995, 99, 2224-2235.
a Results are presented as the mean of three (for 6a) or two (all others) experiments with the standard deviation given where appropriate. For exact yields and analytical characteristics of major adducts, see Supporting Information.b Most compounds reacted completely to give homogeneous mixtures. For 1, 2, and 6c, the filtrates were used due to incomplete reaction owing to low solubility and slow ester hydrolysis.c A minimum S/O ratio was determined from NMR and LC-MS due to low product concentrations (1, 6c) or complex NMR spectra (6a with GSH).